OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
MWN-AI** Summary
OS Therapies Inc. (NYSE American: OSTX) announced a significant regulatory update regarding its immunotherapy candidate, OST-HER2, aimed at preventing recurrence in osteosarcoma patients. The U.S. Food and Drug Administration (FDA) has upgraded OS Therapies' Type D Biomarker Meeting to a Type B pre-Biologics License Application (BLA) meeting. This elevation indicates a pivotal transition in discussions from biomarker data to talks centering around Accelerated Approval for OST-HER2, a product that has been designed to target HER2 protein in pediatric cancer patients with pulmonary metastatic osteosarcoma.
The company is on track to complete the submission of its clinical data package to the FDA by the end of the first quarter of 2026 and anticipates the subsequent pre-BLA meeting will occur shortly thereafter. Paul Romness, CEO of OS Therapies, expressed confidence in the advancement of discussions, noting that the completed biomarker analysis and ongoing patent filings have set a clear path for the establishment of a confirmatory randomized Phase 3 trial. This trial is necessary for the potential Accelerated Approval of OST-HER2 in the U.S.
Notably, OST-HER2 has already garnered Orphan Drug Designation, Fast Track Designation from both the FDA and EMA, and a Rare Pediatric Disease Designation, which could lead to eligibility for a Priority Review Voucher (PRV) worth potentially over $200 million if the drug receives Accelerated Approval. The company aims to secure this approval by the second half of 2026, supporting its commitment to bringing innovative cancer therapies to market.
MWN-AI** Analysis
OS Therapies Inc. (NYSE American: OSTX) is generating momentum in the oncology space, particularly with its lead asset, OST-HER2, targeting pediatric osteosarcoma. The recent elevation of its Type D Biomarker Meeting to a Type B pre-BLA Meeting with the FDA marks a significant turning point in the company’s journey toward potential Accelerated Approval for OST-HER2. This development suggests an encouraging regulatory outlook and reflects confidence in the efficacy of the immunotherapy, especially after its robust Phase 2b trial results.
Investors should be aware of several key indicators that enhance OS Therapies’ valuation potential. First, their ability to secure Orphan Drug Designation and Fast Track status opens doors for expedited regulatory processes and market exclusivity. Moreover, the anticipated Priority Review Voucher (PRV) could fetch significant valuation, as evidenced by recent transactions within the range of $200 million, presenting additional upside for share prices in 2026.
The timeline for the completion of clinical data submission targeting Q1 2026 positions OS Therapies strategically for potential approval announcements later that year. This creates a conducive environment for investors seeking growth opportunities within biotech. However, given the inherent risks in clinical trials and regulatory outcomes, it’s crucial for investors to weigh this growth potential against the unpredictable nature of pharmaceutical approvals.
In summary, OS Therapies appears well-positioned for a bullish trajectory moving forward, with several catalysts on the horizon. Investors should watch for the completion of clinical data submissions, the results of the upcoming pre-BLA Meeting with the FDA, and any announcements regarding Accelerated Approval. Those seeking exposure to innovative oncology therapies may find OSTX an intriguing prospect, albeit with an acknowledgment of the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions
OS Therapies on track to complete clinical data submission by the end of Q1 2026
New York, New York--(Newsfile Corp. - March 9, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided an update regarding ongoing conversations with the United States Food & Drug Administration (FDA) with regards to its ongoing Biologics License Application (BLA) submission under the Accelerated Approval Program (Accelerated Approval) for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. FDA elevated OS Therapies' Type D Biomarker Meeting to a Type B pre-BLA Meeting, expected to occur shortly after the Company completes submission of its clinical data package to the agency, targeted for the end of the first quarter of 2026.
"We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST-HER2 for pediatric cancer patients with osteosarcoma," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "With the biomarker analysis complete, and patent filings in process, we are poised to deliver data to the agency that we believe represents surrogate clinical efficacy sufficient to enable our ongoing BLA submission. Following key meetings with Key Opinion Leaders over the last few weeks, many of whom treated patients in our clinical trial, we believe we now have a clear path forward to establish confirmatory randomized Phase 3 trial that is required to have a commenced prior to being granted Accelerated Approval in the United States."
OST-HER2 has received FDA Orphan Drug Designation (ODD) and Fast Track Designation from the FDA & EMA and has also received Rare Pediatric Disease Designation (RPDD) from the FDA. Under the RPDD program, if the Company receives Accelerated Approval in the United States, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. The most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of $205 million. The Company is seeking to get Accelerated Approval for OST-HER2 in osteosarcoma in the second half of 2026.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates receiving a Biologics Licensing Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving conditional Marketing Authorisations from the U.K.'s Medicines and Healthcare products Regulatory Agency and the European Medicines Agency for OST-HER2 in 2026. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. The Company also anticipates reading out data from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half of 2026.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
media@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287699
FAQ**
What specific data or indications from OS Therapies Incorporated OSTX's biomarker analysis influenced the FDA's decision to elevate the meeting status to a Type B pre-BLA Meeting?
How does OS Therapies Incorporated OSTX plan to leverage the FDA's Accelerated Approval program for OST-HERparticularly following its upcoming randomized Phase 3 trial?
In what ways could the potential Priority Review Voucher from the FDA impact OS Therapies Incorporated OSTX's financial strategy and market positioning after receiving Accelerated Approval?
How does OS Therapies Incorporated OSTX intend to engage with Key Opinion Leaders to ensure successful outcomes following the upcoming Type B pre-BLA meeting with the FDA?
**MWN-AI FAQ is based on asking OpenAI questions about OS Therapies Incorporated (NYSE: OSTX).
NASDAQ: OSTX
OSTX Trading
-6.63% G/L:
$1.55 Last:
471,925 Volume:
$1.65 Open:
